Logo image of CRIS

CURIS INC (CRIS) Stock Fundamental Analysis

NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD

1.63  +0.05 (+3.16%)

After market: 1.71 +0.08 (+4.91%)

Fundamental Rating

2

Overall CRIS gets a fundamental rating of 2 out of 10. We evaluated CRIS against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of CRIS have multiple concerns. CRIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRIS has reported negative net income.
In the past year CRIS has reported a negative cash flow from operations.
In the past 5 years CRIS always reported negative net income.
In the past 5 years CRIS always reported negative operating cash flow.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CRIS has a worse Return On Assets (-105.15%) than 77.82% of its industry peers.
Industry RankSector Rank
ROA -105.15%
ROE N/A
ROIC N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

CRIS's Gross Margin of 99.10% is amongst the best of the industry. CRIS outperforms 97.89% of its industry peers.
In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
CRIS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

1

2. Health

2.1 Basic Checks

CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRIS has been increased compared to 1 year ago.
The number of shares outstanding for CRIS has been increased compared to 5 years ago.
There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -44.94, we must say that CRIS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -44.94, CRIS is doing worse than 93.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.94
ROIC/WACCN/A
WACC10.2%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CRIS has a Current Ratio of 1.39. This is a normal value and indicates that CRIS is financially healthy and should not expect problems in meeting its short term obligations.
CRIS has a worse Current ratio (1.39) than 83.45% of its industry peers.
A Quick Ratio of 1.39 indicates that CRIS should not have too much problems paying its short term obligations.
CRIS has a worse Quick ratio (1.39) than 82.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

CRIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
CRIS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.80%.
CRIS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.75% yearly.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.42%
Revenue 1Y (TTM)8.8%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%24.07%

3.2 Future

Based on estimates for the next years, CRIS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.08% on average per year.
CRIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.12% yearly.
EPS Next Y54.88%
EPS Next 2Y29.38%
EPS Next 3Y20.85%
EPS Next 5Y14.08%
Revenue Next Year13.45%
Revenue Next 2Y11.6%
Revenue Next 3Y23.12%
Revenue Next 5Y51.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
Also next year CRIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

CRIS's earnings are expected to grow with 20.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.38%
EPS Next 3Y20.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRIS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CURIS INC

NASDAQ:CRIS (4/25/2025, 8:00:00 PM)

After market: 1.71 +0.08 (+4.91%)

1.63

+0.05 (+3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)05-09 2025-05-09/bmo
Inst Owners37.99%
Inst Owner Change0%
Ins Owners7.81%
Ins Owner Change0%
Market Cap17.05M
Analysts80
Price Target20.4 (1151.53%)
Short Float %1.68%
Short Ratio2.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.28%
Min EPS beat(2)-42.45%
Max EPS beat(2)9.89%
EPS beat(4)2
Avg EPS beat(4)-11.55%
Min EPS beat(4)-42.45%
Max EPS beat(4)9.89%
EPS beat(8)5
Avg EPS beat(8)-5.37%
EPS beat(12)7
Avg EPS beat(12)-2.24%
EPS beat(16)8
Avg EPS beat(16)-3.98%
Revenue beat(2)2
Avg Revenue beat(2)43.46%
Min Revenue beat(2)26.17%
Max Revenue beat(2)60.74%
Revenue beat(4)3
Avg Revenue beat(4)23.22%
Min Revenue beat(4)-15%
Max Revenue beat(4)60.74%
Revenue beat(8)4
Avg Revenue beat(8)8.45%
Revenue beat(12)4
Avg Revenue beat(12)1.76%
Revenue beat(16)6
Avg Revenue beat(16)0.5%
PT rev (1m)-4.76%
PT rev (3m)-4.76%
EPS NQ rev (1m)6.67%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)30.43%
EPS NY rev (3m)30.43%
Revenue NQ rev (1m)-5.85%
Revenue NQ rev (3m)-5.85%
Revenue NY rev (1m)35.12%
Revenue NY rev (3m)35.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.03
EYN/A
EPS(NY)-3.17
Fwd EYN/A
FCF(TTM)-3.78
FCFYN/A
OCF(TTM)-3.78
OCFYN/A
SpS1.04
BVpS-0.57
TBVpS-1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.15%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.1%
FCFM N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -44.94
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.42%
EPS Next Y54.88%
EPS Next 2Y29.38%
EPS Next 3Y20.85%
EPS Next 5Y14.08%
Revenue 1Y (TTM)8.8%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%24.07%
Revenue Next Year13.45%
Revenue Next 2Y11.6%
Revenue Next 3Y23.12%
Revenue Next 5Y51.12%
EBIT growth 1Y7.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.93%
EBIT Next 3Y-18.99%
EBIT Next 5Y1.48%
FCF growth 1Y-2.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.94%
OCF growth 3YN/A
OCF growth 5YN/A